Background: Candlenut (CN) has been used indiscriminately for weight loss. In vivo effects of CN in different doses are scarce.
Objective: To evaluate the effects of CN ingestion in obese rats.
Design: Thirty animals (obese and non-obese) received one of three different types of treatments: placebo, CN ingestion in a popular therapeutic regimen (8 days with oral administration of 0.2 mg/kg followed by 20 days with doses of 0.4 mg/kg), and ingestion of a doubled popular dose-called 2CN. Treatment was maintained for 28 days.
Results: The fatty acid profile of CN indicated mainly linolelaidic and palmitoleic acids. Rats receiving CN and 2CN showed reduced plasmatic levels of glucose and lipoproteins (p < 0.05). A dose-dependent carcass fat reduction was observed (p < 0.05). Blood levels of aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) reduced with CN and increased with 2CN doses (p < 0.05). Alanine aminotransferase (ALT) and the atherogenic index remained similar among all treatments (p > 0.05). Hepatic vacuolation decreased with CN, but the 2CN dose produced mononuclear leucocyte infiltrate.
Conclusions: Although CN presented beneficial effects on the metabolism of rats, it also caused increased risk of liver damage.
Keywords: Candlenut; Obesity; Pharmacology; Physiology; Plant extracts; Toxicity.
© 2022. The Author(s).